Basilea Pharmaceutica AG/€BSLN
1D1W1MYTD1Y5YMAX
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland. The company focuses on the research, development, and commercialization of innovative medicines, primarily in the areas of infectious diseases and oncology. Some of its key products include antifungal and antibiotic treatments like Cresemba and Zevtera, which address significant medical needs in their respective markets. Basilea was founded as a spin-off from Roche in 2000, reflecting its strong roots in pharmaceutical research. The company's strategic positioning capitalizes on its expertise in addressing drug-resistant bacterial infections and rare fungal infections, providing solutions where few alternatives exist. Basilea operates on a global scale, collaborating with international partners to expand its research and market reach.
- Ticker
- €BSLN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 200
- Headquarters
- Allschwil, Switzerland
- Website
- www.basilea.com
BSLN Metrics
BasicAdvanced
€870M
16.32
€4.29
0.41
-
Price and volume
Market cap
€870M
Beta
0.41
52-week high
€67.00
52-week low
€48.02
Average daily volume
44K
Financial strength
Current ratio
6.596
Quick ratio
5.811
Long term debt to equity
50.126
Total debt to equity
51.396
Interest coverage (TTM)
21.08%
Profitability
EBITDA (TTM)
65.13
Gross margin (TTM)
38.51%
Net profit margin (TTM)
21.17%
Operating margin (TTM)
24.20%
Effective tax rate (TTM)
10.72%
Revenue per employee (TTM)
€1,325,690
Management effectiveness
Return on assets (TTM)
13.69%
Return on equity (TTM)
39.46%
Valuation
Price to earnings (TTM)
16.316
Price to revenue (TTM)
3.254
Price to book
5.01
Price to tangible book (TTM)
5.02
Price to free cash flow (TTM)
14.608
Free cash flow yield (TTM)
6.85%
Free cash flow per share (TTM)
4.788
Growth
Revenue change (TTM)
4.74%
Earnings per share change (TTM)
-26.73%
3-year revenue growth (CAGR)
12.23%
10-year revenue growth (CAGR)
15.65%
3-year earnings per share growth (CAGR)
-3.53%
10-year earnings per share growth (CAGR)
-3.71%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.